Key statistics
Previous close$184.56
Open$185.92
Day high$191.55
Day low$184.42
52-week high$191.55
52-week low$120.05
Market cap14.35B
Volume396.43K
Average volume609.08K
P/E ratio12.40
Forward P/E—
EPS14.90
Dividend yield+0.65%
Market context
Why it moved
Globe Life's stock edged up modestly, supported by institutional buying from firms like SteelPeak Wealth LLC increasing its stake and several analysts including Piper Sandler, Morgan Stanley, and Keefe, Bruyette & Woods raising their price targets to a consensus Moderate Buy rating.
What is happening
Recent company-specific developments and publisher coverage.
July 17, 2026Globe Life closed at a new 52-week high, gaining nearly 2% on the session amid a wave of bullish analyst price target upgrades and a favorable backdrop for insurers. Multiple Wall Street firms raised their targets recently — Piper Sandler to $200, Morgan Stanley to $208, TD Cowen to $215, Keefe Bruyette & Woods to $192, and Wells Fargo to $193 — reflecting confidence in the company's earnings trajectory and its planned Bermuda reinsurance affiliate, which is expected to significantly boost free cash flow and share repurchase capacity by 2027. The insurer's strong 1-year return of ~52% and a refreshed credit facility signal improving fundamentals, though ongoing DOJ/SEC investigations remain a key risk watch for investors.1.6803
July 15, 2026Globe Life closed higher with above-average volume, approaching its 52-week high as a wave of upward analyst price target revisions bolstered investor confidence ahead of next week's earnings report. Piper Sandler raised its target to $200 (from $175, Overweight), Keefe Bruyette & Woods lifted its target to $192 (from $180, Outperform), and Wells Fargo raised its target to $193, while Evercore ISI also increased its target to $176 — all within days of each other. Investors are also monitoring Globe Life's recently overhauled credit agreements with Wells Fargo and its planned Bermuda reinsurance affiliate, expected to meaningfully boost free cash flow and share repurchase capacity by 2027. Ongoing DOJ and SEC investigations remain a watchlist item for some investors, though momentum has been broadly constructive.1.4079
July 15, 2026Globe Life closed modestly higher, edging up amid a wave of analyst price target increases that reflect growing confidence in the company's strategic direction. Keefe Bruyette raised its target to $192 (Outperform), Wells Fargo lifted its target to $193, Morgan Stanley boosted to $208, and Evercore ISI raised to $176 while maintaining an In Line rating — all pointing to improving fundamental expectations. The key catalyst driving optimism is Globe Life's planned Bermuda reinsurance affiliate, which is expected to significantly boost parent company free cash flow and capital return capacity by 2027. The company also recently amended and restated its credit and term loan agreements with Wells Fargo, extending maturities and increasing borrowing flexibility. Ongoing DOJ and SEC investigations remain a watchpoint for investors, and some analysts flag the stock as modestly overvalued near current levels relative to a $172 fair value consensus estimate, even as the average analyst target of ~$186 suggests further upside.0.2071
July 14, 2026Globe Life closed modestly lower as a wave of analyst price target increases failed to lift the stock amid a risk-off session driven by renewed U.S.-Iran tensions and surging oil prices. Keefe Bruyette raised its target to $192 (maintaining Outperform) and Evercore ISI lifted its target to $176 (maintaining In-Line), continuing a string of upward revisions that also included Morgan Stanley ($208) and Wells Fargo ($193) last week. With Q2 earnings season approaching, FactSet notes life insurers like Globe Life should benefit from stable unemployment and solid persistency trends, though the stock remains in a wait-and-see mode ahead of its upcoming results.-0.2847
July 11, 2026Globe Life closed modestly higher, holding near its 52-week high of $182.32, as investors focus on the upcoming Q2 2026 earnings release scheduled for July 22. Wells Fargo raised its price target to $193 (Overweight) while Jefferies lifted its target to $166 (Hold), reflecting divergent views ahead of results. A Zacks analysis highlighted Globe Life's 48.7% one-year gain, noting the stock outperforms its industry while trading at a valuation discount — supported by premium growth, AI initiatives, and capital returns.0.151
July 9, 2026Globe Life edged higher, outperforming the broader financial sector as investors responded to a confluence of bullish analyst activity and renewed interest in defensive insurance names. Wells Fargo raised its price target on Globe Life to $193 from $172 (maintaining Overweight), while Morgan Stanley also kept its Overweight rating with a $208 target — both citing premium growth, underwriting discipline, and investment income. The stock has surged ~48.7% over the past year, and with Q2 2026 earnings scheduled for July 22, investors are closely watching whether Globe Life can sustain its outperformance amid a volatile macro backdrop marked by US-Iran tensions, rising oil prices, and inflation concerns.1.0109
July 8, 2026Globe Life edged higher as investors rotated into insurance names amid a volatile macro backdrop, with broader markets weighed down by escalating U.S.-Iran tensions and a tech-driven selloff. With Q2 earnings scheduled for July 22, investor focus is sharpening around the company's raised 2026 EPS guidance of $15.40–$15.90 and its recently expanded credit facility—boosting term loan capacity to $450M with maturities extended to 2031—while the consensus analyst price target was lifted to $181.08 with a Buy rating maintained across 14 covering analysts.0.2264
July 8, 2026Globe Life closed essentially unchanged on Tuesday but is slipping further in after-hours trading, down nearly 2%, as mixed analyst sentiment and ongoing regulatory concerns weigh on investor confidence. Morgan Stanley raised its price target to $208 (Overweight), lifting the 12-analyst average target to $181.08, yet some analysts caution the stock is modestly overvalued and flag below-peer revenue growth of 4.5% annually. Globe Life's June 2026 credit facility expansion — increasing its term loan capacity from $250M to $450M with maturities extended to 2029–2031 — signals management's focus on financial flexibility, though lingering DOJ and SEC investigations remain a key risk overhang for investors.-0.1752
Ad Hoc News · July 17, 2026Globe Life stock steadies as investors weigh earnings growth and capital return↗Investing.com · July 16, 2026Globe Life stock hits all-time high at 183.18 USD↗Simply Wall Street · July 14, 2026Globe Life (GL) Could Be 4% Overvalued Following Its Bermuda Reinsurance Plan↗marketscreener.com · July 13, 2026Keefe Bruyette & Woods Adjusts PT on Globe Life to $192 From $180, Maintains Outperform Rating↗Moomoo · July 13, 2026Keefe Bruyette & Woods Adjusts PT on Globe Life to $192 From $180, Maintains Outperform Rating↗Stock Titan · July 8, 2026Globe Life sets July 23 call after Q2 results on July 22↗ Mt Newswire · July 15, 2026Piper Sandler Adjusts Price Target on Globe Life to $200 From $175, Maintains Overweight RatingBenzinga · July 15, 2026Piper Sandler Maintains Overweight on Globe Life, Raises Price Target to $200Benzinga · July 13, 2026Evercore ISI Group Maintains In-Line on Globe Life, Raises Price Target to $176Mt Newswire · July 13, 2026Keefe Bruyette & Woods Adjusts PT on Globe Life to $192 From $180, Maintains Outperform RatingMt Newswire · July 13, 2026Evercore ISI Adjusts Price Target on Globe Life to $176 From $157, Maintains In Line RatingBenzinga · July 10, 2026Jefferies Maintains Hold on Globe Life, Raises Price Target to $166Mt Newswire · July 10, 2026Jefferies Adjusts Globe Life Price Target to $166 From $147Benzinga · July 9, 2026Wells Fargo Maintains Overweight on Globe Life, Raises Price Target to $193
